AUPH Stock — Aurinia Pharmaceuticals Inc: Cash, EV, Pipeline

Share price

$16.90

Market cap

$2,248.6M

Cash

$179.7M

Enterprise value

$2,068.9M

Balance sheet

Cash	$179.7M
Debt	$0.0M
Net cash	$179.7M
Enterprise value	$2,068.9M
Basic shares	132.9M shares
Fully diluted shares	146.1M shares
Fully diluted market cap	$2,468.5M
Cash per share	$1.35

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading AUPH daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Apr 13 - May 25	Aritinercept	Phase 2	Myasthenia Gravis, Generalized	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

LUPKYNIS

Approved · Active Modality: calcineurin inhibitor (CNI) immunosuppressant

Aliases voclosporin

Target calcineurin

Partnerships Otsuka Pharmaceutical: collaboration and licensing (Dec 2020) to develop/commercialize oral voclosporin in Japan, EU, UK, Switzerland, Russia, Norway, Belarus, Iceland, Liechtenstein, Ukraine; commercial supply agreement (Aug 2022)

Indications

Active lupus nephritis (adult) (Approved)

Status note First FDA-approved oral therapy for active LN (Jan 2021). PRESERVE Phase 4 study initiated: LUPKYNIS plus belimumab, obinutuzumab or anifrolumab in LN.

aritinercept

Phase 1 · Active Modality: dual BAFF/APRIL inhibitor (BCMA-engineered binding domain, IgG4 Fc)

Target BAFF and APRIL

Indications

Autoimmune diseases (four indications; not named in filing) (Phase 1)

Status note Acquired via Kezar Life Sciences acquisition (completed May 11, 2026). Clinical development initiated in four potential indications. Clinical study in one autoimmune disease initiated; additional study planned in H1 2026.

AUR300

Stage not disclosed · Terminated

Status note Discontinued in Feb 2024 strategic restructuring (headcount reduced ~25%).

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Aritinercept
Lead indication	Myasthenia Gravis, Generalized
Lead phase	Phase 2
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07596901	Phase 2	Recruiting	Sponsor	AUPH	—	Myasthenia Gravis, Generalized	—
NCT07611214	Not disclosed	Recruiting	Sponsor	AUPH	—	Lupus Nephritis	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Aurinia Pharmaceuticals Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

AUPH — Aurinia Pharmaceuticals Inc